



The attached document contains a new Request for Proposal (RFP) from Pfizer's Global Medical Grants program. While Pfizer recognizes many institutions and healthcare professionals around the globe are prioritizing challenges associated with the COVID-19 pandemic, we are cognizant that the healthcare and patient community will continue to benefit from ongoing support for research, improvement science, and education in spite of this crisis. It is in this spirit that Pfizer will continue our grants program by publishing RFPs that have been planned for 2020.

Thank you in advance for all that you are doing to improve the care of patients. Pfizer is proud to be able to support these efforts through this grants program.

Please contact the Global Medical Grants team at GMG@pfizer.com if you have any questions or would like to be temporarily removed from our mailing list.



PFIZER



Pfizer Announces
Incorporating Biosimilar Treatment Options in Solid Tumor Education Programs
Medical Education Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.

Pfizer’s GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the knowledge gaps as outlined in the specific RFP.

For all independent medical education grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct of the independent education program.



II. Eligibility

Geographic Scope:	<p>Primary Focus: Europe, United States</p> <p>Secondary Focus: Japan, Asia-Pacific region, Latin America, and rest of world</p>
Applicant Eligibility Criteria	<ul style="list-style-type: none"> • The following may apply: medical, nursing, allied health, and/or pharmacy professional schools; healthcare institutions (both large and small); professional associations and medical societies; patient education or patient advocacy associations; medical education companies; and other entities with a mission related to healthcare professional education and/or healthcare improvement. • If the project involves multiple departments within an institution and/or between different institutions / organizations / associations. all institutions must have a relevant role and the requesting organization must have a key role in the project. • For projects offering continuing education credit, the requesting organization must be accredited.

III. Requirements

Date RFP Issued	<ul style="list-style-type: none"> • May 28, 2020
Clinical Area	<ul style="list-style-type: none"> • Oncology – General - Biosimilars
General Area of Interest for this RFP:	<p>The goal of this RFP is to support education programs that advance the integration of biosimilars as standard of care in the following cancer types.</p> <p>Priority 1:</p> <ul style="list-style-type: none"> • Colorectal • Lung • Breast <p>Priority 2:</p> <ul style="list-style-type: none"> • Gynecological • Glioblastoma • Gastric/Gastro-esophageal junction • Renal • and other solid- tumor cancer types in which a biosimilar is indicated. <p>The RFP is seeking proposals where education on biosimilars is integrated into and delivered as part of a broader oncology educational program on the treatment of the aforementioned cancer types.</p> <p>For example, if the planned educational topic is “Updates in Treatment of</p>

	<p>Colorectal Cancer”, include one learning objective around increasing the awareness of biosimilar treatment options. Or if your organization has an existing educational event focused on the treatment of HER2+ breast cancer, incorporate a presentation on when a biosimilar should be considered.</p> <p>Proposals should aim to increase clinician and patient understanding of complex biosimilar concepts including but not limited to:</p> <ul style="list-style-type: none"> • Real world experience with biosimilars in treatment of relevant tumor types • Extrapolation of indications (e.g. for biosimilar indicated in colorectal cancer but not clinically studied in colorectal cancer or standard of care combination regimen not specifically studied) • Interpretation of key functional and structural analytical data, and implications for clinical practice • Implementing practical approaches to the incorporation of biosimilars into practice, including protocols, formularies, guidelines and pathways <p>All educational activity types will be considered through this RFP including but not limited to:</p> <ul style="list-style-type: none"> • In-person or virtual national or regional conferences, workshops, regional community series; digital tools, handouts & other printed materials • Activities for healthcare professionals that also include educational materials or resources for patients • Applications from professional societies and patient associations focused on providing education and/or resources to their members are encouraged.
<p>Target Audience:</p>	<ul style="list-style-type: none"> • Oncologists and other Physicians, Oncology Nurses, Oncology Pharmacists, Nurse Practitioners, Physician Assistants, Administrators or Practice Managers, Patients / Patient advocates
<p>Expected Approximate Monetary Range of Grant Applications:</p>	<ul style="list-style-type: none"> • The estimated total available budget related to this RFP is \$1,300,000. Individual projects requesting up to \$250,000 will be considered, however, smaller educational proposals are also encouraged. Organizations that would like to develop activities for a more limited regional or local group of healthcare providers should also apply. Typically grant amounts for local or regional activities should not exceed around \$50,000 USD.

<p>Key Dates:</p>	<ul style="list-style-type: none"> • RFP release date: May 28, 2020 • Grant Application due date: July 7, 2020 Please note the deadline is 23:59 Eastern Standard Time (e.g., New York, GMT -5). • Anticipated Grant Award Notification Date: July 28, 2020 • Grants will be distributed following a fully executed agreement. • Anticipated Project Start and End Dates: September 2020 to December 2021 (dates are suggested only, project timelines can be up to 2 years)
<p>How to Submit:</p>	<ul style="list-style-type: none"> • Please go to www.cybergrants.com/pfizer/knowledge and sign in. First-time users should click “Create your password”. • In the application: <ul style="list-style-type: none"> ○ For the question “What type of request are you submitting?” select Response to a Request for Proposal (RFP) ○ For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes ○ Select the following Competitive Grant Program Name: 2020 Oncology G - Biosimilar Treatment Options in Solid Tumor Education Programs ○ Select the following Primary Area of Interest: Oncology – General - Biosimilars • Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the General RFP Submission field. • If you encounter any technical difficulties with the website, please click the “Technical Questions” link at the bottom of the page. <p>IMPORTANT: Be advised applications submitted after the due date will not be reviewed by the committee.</p>
<p>Questions:</p>	<ul style="list-style-type: none"> • If you have questions regarding this RFP, please direct them in writing to the Grant Officer, Jackie Waldrop (Jacqueline.Waldrop@pfizer.com) with the subject line “Incorporating Biosimilar Treatment Options”
<p>Review and Approval Process</p>	<ul style="list-style-type: none"> • Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
<p>Mechanism by which Applicants will be Notified:</p>	<ul style="list-style-type: none"> • All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period.

Appendix A

General RFP Submission Requirements

Project Proposals should be single-spaced using Calibri 12-point font and 1-inch margins. Note there is a 15-page limit exclusive of references. Please include the following:

Goals and Objectives	<ul style="list-style-type: none"> Briefly state the overall goal of the project. List the objectives you plan to meet with your project, in terms of learning and expected outcomes.
Needs Assessment for the Project	<ul style="list-style-type: none"> Include a description of your organization's needs assessment for this proposed project which may include a quantitative baseline data summary, initial metrics, or a project starting point (please cite data on gap analyses or relevant patient-level data that informs the stated objectives) in your target area.
Target Audience	<ul style="list-style-type: none"> Describe the primary audience(s) targeted for this project. Indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population.
Project Design and Methods	<ul style="list-style-type: none"> Describe the planned project, the educational approach, and the way the planned methods address the established need.
Innovation	<ul style="list-style-type: none"> Explain what measures you have taken to assure that this project is original and does not duplicate other projects or materials already developed. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions.
Evaluation and Outcomes	<ul style="list-style-type: none"> In terms of the metrics used for the needs assessment, describe how your organization will determine if the gap was addressed for the target group. Identify the sources of data your organization anticipates using to make the determination. Describe how your organization is expected to collect and analyze the data. Explain the method used to control for other factors outside this project (e.g., use of a control group or comparison with baseline data). Quantify the amount of change expected from this project in terms the target audience. Describe how your organization will determine if the target audience was fully engaged in the project.
Dissemination Plan	<ul style="list-style-type: none"> Describe how the project may have extended benefit beyond the grant. Will the teaching materials be made available to others to use? Will there be tools or resources that are made publicly available beyond the

	<p>initial project. Describe how the project outcomes might be broadly disseminated.</p>
Anticipated Project Timeline	<ul style="list-style-type: none"> • Provide an anticipated timeline for your project including project start/end dates.
Additional Information	<ul style="list-style-type: none"> • If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here.
Organization Detail	<ul style="list-style-type: none"> • Describe the attributes of the institutions/organizations that will support and facilitate the execution of the project, the leadership of the proposed project, and the specific role of each institution in the proposed project.
Budget Narrative	<ul style="list-style-type: none"> • Please include a budget narrative that describes in greater detail the line items specified in the budget submitted within the application • While estimating your budget please keep the following items in mind: <ul style="list-style-type: none"> ○ Independent Medical Education Grants awarded by GMG cannot be used to purchase therapeutic assets (prescription or non-prescription). ○ Overhead rates of up to 28% of the total proposed project budget may be supported by Pfizer.